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Abstract This exploratory study aims to create an evi-
dence-based comprehensive characterization of hyperka-
lemic periodic paralysis (hyperPP). HyperPP is a rare genetic
disorder that causes episodes of flaccid paralysis. Disease
descriptions in the literature are based upon isolated clinical
encounters and case reports. We describe the experience of a
large cohort of genetically diagnosed individuals with hy-
perPP. We surveyed genetically characterized individuals
age 18 and over to assess disease comorbidities, diagnostic
testing, management, and quality of life issues relevant to
hyperPP. Myotonia was reported by 55.8 % of subjects and
paramyotonia by 45.3 %. There is a relative risk of 3.6
(p \ 0.0001) for thyroid dysfunction compared to the gen-
eral population. Twenty-five percent of subjects experienced
their sentinel attack in the second decade of life. It took an
average of 19.4 years and visits to four physicians to arrive at
the diagnosis of hyperPP. In addition to limbs and hands
being affected during attacks, 26.1 % of subjects reported
their breathing musculature was affected and 62.0 %
reported their facial muscles were affected. There was a
lifelong trend of increasing attack frequency, which was
particularly common during childhood and adolescence.
Approximately one-third of individuals experienced pro-
gressive myopathy. Permanent muscle weakness was evi-
dent and worsened during childhood and after age 40. Those
with no chronic treatment regimen have a RR of 2.3 for
inadequate disease control compared to those taking long-
term medications. This study revealed a multitude of here-
tofore unidentified characteristics of hyperPP, in addition to
providing a different perspective on some previously held
notions regarding the condition.
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Introduction
Hyperkalemic periodic paralysis (hyperPP) is an autosomal
dominant muscle sodium channelopathy with nearly com-
plete penetrance [1]. Tyler et al. [2] first described the disease
in 1951 in their study of a kindred of 7 generations of indi-
viduals with clinically typical periodic paralysis in the
absence of hypokalemia. In 1957, Gamstorp extensively
investigated the condition and named it adynamia episodica
hereditaria [3]. The name was later changed to hyperkalemic
periodic paralysis in light of the provocative effects of
potassium intake as well as the rise in serum potassium levels
associated with spontaneous attacks [1]. Point mutations in
the SCN4A gene encoding the alpha subunit of the skeletal
muscle voltage-gated sodium channel Nav1.4 lead to
defective channel function. This disrupts the normal
exchange of ions in skeletal muscles, consequently reducing
their ability to contract and resulting in attacks of muscle
weakness or paralysis [4, 5]. The condition affects approxi-
mately 1 in every 200,000 people [1]. Although typically
hereditary, de novo mutations have been reported [6].
The following disease description summarizes the lit-
erature on hyperPP to date; our study calls some of this
information into question. HyperPP is characterized by
attacks of flaccid muscle weakness that are in fact episodic,
rather than periodic, in nature. Attacks typically begin in
the first decade of life, progressing in frequency until their
frequency plateaus in early adulthood. Sometime after
midlife, attack frequency declines substantially [7, 8].
Often older individuals experience a chronic progressive
myopathy that can cause permanent muscle weakness [8].
Attacks vary in severity, and the same mutation can
have variable expressivity within and between families [5].
Attacks can last anywhere from 30 min to several hours
[6], typically lasting 1–2 h [9] and infrequently days [10].
Unlike those with hypokalemic periodic paralysis (hy-
poPP), those with hyperPP infrequently experience gen-
eralized flaccid paralysis but rather tend to have focal
weakness; the thigh and calf muscles are often affected.
Reflexes during an attack may be absent or diminished,
and, rarely, the bulbar and respiratory muscles may be
affected. Sphincter muscles maintain tonicity during
attacks. Sensation is not affected during attacks, although
individuals may experience an aura of muscle paresthesia
and discomfort prior to the onset of weakness [11].
HyperPP has three clinically distinct manifestations: (1)
without myotonia, (2) with clinical or electromyographic
(EMG) myotonia, or (3) with paramyotonia congenita
(PMC). In all three forms, the course of the paralytic
attacks is the same [7, 11]. Electrical myotonia can be
demonstrated on EMG in 50–75 % of patients with hy-
perPP, while less than 20 % manifest clinically [10]. In
those with myotonia, i.e., a tonic spasm of muscle [12], the
myotonia is often mild and can be provoked with percus-
sion or activity in the face, tongue, forearms, and thenar
eminence. The myotonia eases with repetitive activity [11].
From birth onwards, those with PMC experience muscle
stiffness that increases with continued activity (paramyo-
tonia) and is cold-induced [1]. Paralytic attacks can occur
at any time, though often occur spontaneously in the
morning prior to breakfast, last up to an hour, and unpre-
dictably subside [8, 11]. Attacks may be provoked or
worsened by anesthesia [5], rest after exercise, potassium
loading, cold environments, hunger, emotional stress, glu-
cocorticoids, or pregnancy. During attacks, individuals
may be hyperkalemic or normokalemic [4]. The concom-
itant rise in serum potassium levels can range from upper
normal values to those in the cardiotoxic spectrum [6].
After an attack, serum potassium levels may be transiently
low due to the elimination of potassium from the kidneys
and the reuptake of potassium by muscle [7]. Usually,
individuals do not experience cardiac arrhythmias or
respiratory insufficiency during attacks [8]. After an attack,
individuals may feel pain for up to several days in the
involved muscle groups [11]. Between attacks, affected
individuals have normal serum potassium levels, normal
sensation and muscle stretch reflexes, and normal muscle
strength, although they may experience minor myotonia
that does not hinder voluntary movement. ‘‘Lid lag’’ sec-
ondary to eyelid myotonia may be the only clinical sign
present between attacks [8, 11].
The diagnosis of hyperPP is based on clinical grounds,
sometimes with the use of provocative tests in cases of
diagnostic uncertainty [8]. The diagnosis is suggested by a
history of attacks of weakness or paralysis, a positive
family history, and the presence of myotonia or paramy-
otonia. Serum creatine kinase (CK) values may be ele-
vated, and some individuals exhibit calf hypertrophy. The
muscles are typically well-developed [6, 11]; however, a
large proportion of individuals with hyperPP develop a
chronic progressive proximal myopathy as they age [10,
13]. Parenthetically, individuals without interictal myoto-
nia are much more susceptible to developing this pro-
gressive myopathy than are individuals with myotonia [1,
8]. Muscle biopsy is non-specific, though will frequently
reveal muscle fiber atrophy with vacuoles [5, 11]. Genetic
testing is positive in approximately 60 % of individuals
who meet clinical diagnostic criteria. An EMG may show
myotonic signs, which strongly support the diagnosis,
although approximately half of those with the most
common mutation show no such signs [8]. Provocative
tests, such as the potassium challenge test, pose obvious
risks to the patient but may be done to support the diag-
nosis. The availability of genetic testing and electro-
physiologic studies largely obviates the need for such
dangerous tests [5, 11].
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Prophylactic measures include eating frequent carbo-
hydrate-rich meals and the continuous use of diuretics that
reduce serum potassium levels, such thiazides or carbonic
anhydrase inhibitors. Equally important is avoidance of
potassium-rich foods, medications that raise serum potas-
sium, fasting, strenuous work, and exposure to cold.
Mexiletine is beneficial in the management of myotonia.
Early in the course of an attack, abortive or attenuating
measures include mild exercise, carbohydrate ingestion,
and beta-adrenergic agonist inhalation. Severe attacks
warrant treatment with intravenous glucose and insulin.
Calcium carbonate is used in cases of severe hyperkalemia
to stabilize the myocardium to prevent arrhythmia [6, 8,
11]. Patients with hyperPP must avoid depolarizing anes-
thetics, such as suxamethonium and anticholinesterase
agents, as they aggravate myotonia and can interfere with
intubation and mechanical ventilation [8].
The present study describes the collective experience of
a relatively large cohort of individuals genetically diag-
nosed with hyperPP. Study objectives include to confirm or
refute previously reported descriptions of the disease, to
discover new and previously unreported features and
associations, and to provide a better understanding of the
experience of patients with hyperPP.
Methods
To characterize the epidemiology, symptoms, diagnostic
studies, therapeutic options, and special situations associated
with hyperPP, we selected and developed questionnaire
items on the basis of a literature search. We then created a
survey on SurveyMonkey (http://www.surveymonkey.
com) comprised of multiple choice and short answer ques-
tions. To confirm participants indeed had hyperPP, study
participants were asked to provide their specific genetic
mutation. Only responses of published mutations or unpub-
lished severe amino acid substitutions in typical hyperPP
protein areas were included in this report. As the objective of
this study was to better characterize a disorder that is not fully
characterized, most questions included space for subjects to
add comments to their selected responses.
The Mount Sinai School of Medicine’s Institutional
Review Board approved the study protocol, and, per pro-
tocol, the study was performed according to the ethical
standards of the revised 1964 Declaration of Helsinki.
Invitations to take the survey were sent via listserv
announcements and mailings to members of the following
organizations: Periodic Paralysis Association, Periodic
Paralysis News Desk, University of Ulm (Germany),
Strong Memorial Hospital (University of Rochester), Uni-
versity of Texas Southwestern, University Pierre et Marie
Curie (France), and National Hospital for Neurology and
Neurosurgery (University College London). All individuals
provided their informed consent prior to inclusion in the
study. Survey responses were completed either on-line or
on paper. Subjects in Germany were provided with a
German translation of the survey; their responses were later
translated to English for data analysis. The study remained
open for approximately 4 months.
Adults (persons 18 years of age or older) with a genetic
diagnosis of hyperPP were eligible for this study. For
purposes of this study, a genetic diagnosis specifically
refers to mutations: A488T, E1702K, F1311V, G1306A,
G1456E, I1160V, I1495T, I693T, L1436P, L1489H,
L433R, M1360V, M1592V, R1448C, R1448H, S804F,
T1313M, T704M, and V1293I, as well as two mutations
that have yet to be published.
We collected a total of 137 survey responses. Of these
persons, 68.6 % (94/137) provided eligible mutations. Some
respondents did not respond to all survey questions. Study
calculations for individual questions were typically based
only on respondents, e.g., if there were 94 total participants,
and only 80 responded to a question, 8 of whom said ‘yes’,
then this was reported as a 10 % positive response rate for
that question. Absolute values for key study data can be
found in the electronic supplementary material. We cannot
evaluate how our sample compares to the known hyperPP
population considering there is no prior large-scale study of
this population. P values were calculated on http://graphpad.
com/quickcalcs/chisquared1.cfm using chi-square compu-
tations with a familywise error rate of 0.05. In the case of
multiple comparisons, a Bonferroni correction was made,
i.e., the familywise error rate was divided by the number of
choices offered to subjects in that question.
Results and discussion
Demographics, family history, and comorbidities
The study population was 53.3 % male and 46.7 % female
with an age range of 19–84, median age of 46, mode of 48,
and mean of 44.9. The majority of subjects (85.7 %)
reported residing in Germany. In order to characterize
subjects’ degree of disability, we asked whether or not they
receive Social Security Disability payments, and 15 %
responded that they do. A total of 91.5 % of respondents
reported having at least one relative with hyperPP. Of the
remaining individuals, most reported multiple relatives
with PMC without hyperPP. Those with no family history
of hyperPP or PMC appear to have de novo mutations.
To identify comorbidities prevalent in this population, we
surveyed subjects for common medical conditions. The most
common positive responses included thyroid abnormalities,
cardiac arrhythmias, migraines, and high triglycerides/
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cholesterol. Thyroid dysfunction affects 20.2 % of this
population, putting them at a relative risk (RR) of 3.6
(p \ 0.0001) compared to the general population [14].
Cardiac arrhythmias were reported by 9.6 % of the study
population, which was not statistically significant compared
to that of the general population (p = 0.04; per Bonferroni
correction, statistical significance requires p \ 0.005) [15].
Neither the prevalence of migraine nor hyperlipidemia is
increased compared to the general population [16, 17].
Physicians caring for patients with hyperPP should be aware
of the increased risk of thyroid dysfunction.
Diagnosis and symptoms
Participants reported their age of first attack as shown in
Fig. 1. Twenty-five percent experienced their sentinel
attack in the second decade of life, in contrast to the
accepted notion that attacks usually begin in the first dec-
ade of life [8].
The average diagnostic journey for our cohort from the
time of the first onset of symptoms until reaching the
correct diagnosis lasted 19.4 years, ranging from an
immediate diagnosis due to diagnosed relatives to as long
as 65 years. Study participants saw an average of 4 health
care professionals, some seeing as many as 10, before
obtaining their correct diagnosis. The majority of partici-
pants regarded neurologists as the most valuable physicians
in reaching their proper diagnosis; several considered
either a geneticist or pediatrician as most valuable. Sub-
jects reported undergoing a range of diagnostic studies,
most commonly undergoing blood tests, EMGs, and elec-
trocardiograms (EKGs). Surprisingly, 23.4 % of the study
population underwent potassium challenges tests, which
put them at risk for a severe attack. Before arriving at a
diagnosis of hyperPP, subjects were misdiagnosed with
conditions such as malingering, conversion disorder, hy-
poPP, myotonia congenita, and depression. A significant
number of these misdiagnoses are psychiatric conditions.
Generalizing from this cohort, unless recognized quickly
due to family history, the path from attack onset to proper
diagnosis is a long one, often taking years, involving a
multitude of diagnostic studies and misdiagnoses, and
ultimately necessitating a neurologist to clinch the
diagnosis.
We surveyed the prevalence of paramyotonia and myo-
tonia in individuals with hyperPP. Overall, 45.3 % of
respondents reported paramyotonia, over half of whom
reported myotonia as well. One subject reported having
trouble letting go of the toothbrush after brushing his teeth
and mentioned that this was the first presentation of his
daughter’s hyperPP. Myotonia was slightly more prevalent
amongst subjects than paramyotonia; overall, 55.8 % of
respondents reported symptoms of myotonia, exactly half of
whom reported paramyotonia as well. Of note, myotonia
presents clinically in markedly more people than the 20 %
of individuals reported in prior literature [10]. Parentheti-
cally, 31.4 % of respondents were unsure whether or not
they experienced myotonia, and therefore its prevalence
may be underrepresented in this survey. Of individuals with
myotonia, 37.5 % have experienced progressive myopathy,
while of those denying myotonia, 33.3 % have experienced
progressive myopathy, which contradicts previous literature
reporting that those with myotonia are less susceptible to
progressive myopathy [1, 8]. Myotonia may also be exac-
erbated in pregnancy; as one subject said of being pregnant,
‘‘my muscles contract constantly.’’ Myotonia and paramy-
otonia appear to affect a larger proportion of individuals
with hyperPP than previously recognized.
To identify attack triggers that exist in addition to those
previously reported, we surveyed subjects regarding items
Fig. 1 Individuals reported the
age at which they experienced
their first attack. Sentinel
attacks were reported as late as
age 19, with 25 % of subjects
reporting their first attack at age
10 or older (No., number)
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they have recognized as triggers. Seventy-five point eight
percent of subjects reported cold environments, 67.0 % rest
after exercise, 47.3 % stress or fatigue, 45.1 % alcohol,
42.9 % hunger, 40.7 % changes in activity level, 35.2 %
potassium in food, 35.2 % specific foods or beverages,
35.2 % changes in humidity, 34.1 % extra sleep, 27.9 %
(of female respondents) pregnancy, 27.5 % illness of any
type, 18.6 % (of female respondents) menstruation, 16.5 %
medication, and 14.3 % potassium supplements. The fact
that the menstrual cycle and pregnancy were both identified
as triggers suggests a role for estrogenic factors in exac-
erbating hyperPP. Regarding the typical time at which
attacks occur, 55.8 % reported the morning, 45.3 %
reported during sleep, and 43.0 % reported upon waking,
while only 29.1 % identified the afternoon and 19.8 % the
evening as typical times for attacks. Sleep shows a pro-
pensity to serve as an attack trigger, possibly analogous to
rest after exercise on a greater scale.
With respect to prodromal symptoms, the majority of
participants reported experiencing symptoms before the
onset of a frank attack. During the day prior to an attack,
38.6 % experience symptoms such as fatigue, weakness,
irritability, and/or restlessness. Immediately preceding an
attack, 85.7 % experience symptoms such as sweating,
muscle pain, stiffening, weakness, restlessness, tingling
and/or numbness. After such symptoms, most participants
experience attack onset within the next 20 min, although
some take as long as several hours. Of note, the duration of
attack latency from the time of prodrome onset can vary for
an individual. In asking subjects to detail their mood before
or during attacks, many participants reported being irrita-
ble, lethargic, or depressed. Although the experience varies
between individuals and between attacks, the general
consensus describes one of sweating and/or a change in
muscle sensation within the 20 min prior to attack onset.
We surveyed subjects regarding attack frequency and
duration. Some subjects commented that their attacks occur
less frequently than they otherwise would as they are now
medically controlled. Attack frequency spanned the gamut,
ranging from 1–3 attacks per month (29.9 %) to once per
week (20.7 %) to 2–6 per week (24.1 %). In contrast to
prior literature typifying attacks as 1–2 h in duration and
infrequently lasting for days, 22.2 % reported typical
attacks lasting over 2 days, 21.0 % of subjects reported
typical attacks lasting 30 min to an hour, and 13.6 %
reported attacks lasting 15–30 min. A total of 22.9 %
reported their longest attack lasting for over a week.
Subjects most commonly described their attacks as stiff-
ness followed by weakness, although many described their
attacks as some other permutation of weakness and/or stiff-
ness. Regions of the body typically affected by attacks are
shown in Fig. 2. The arms and hands are just as frequently
affected as the thighs and calves. In contrast to prior literature
[11], 26.1 % of subjects reported that their breathing mus-
culature was affected and 62.0 % reported that their face was
affected during attacks, 2.2 % reported being unable to speak
during a typical attack. Current clinical understanding is that
sphincter tone is not altered during attacks [11], however,
two subjects reported bowel incontinence and seven reported
bladder incontinence during attacks.
The reported severity of attacks varied greatly between
individuals. While the largest subset (43.3 %) of respon-
dents described the majority of their attacks as mild
(defined as ‘‘have only some limitations on mobility, others
would notice I am in an attack’’), 15.6 % reported their
attacks to be either severe (defined as ‘‘can speak, cannot
move at all, can call for help’’) or very severe (defined as
‘‘cannot speak, cannot call for help’’). The majority of
individuals reported mild or no symptoms between attacks.
However, 12.4 % reported severe symptoms between
attacks that impair their activities of daily living, which
stands in contrast to prior literature reporting that ‘‘lid lag’’
secondary to eyelid myotonia may be the only clinical sign
present between attacks [8, 11].
After an attack, most subjects reported experiencing
various symptoms that have not previously been reported
in literature. Most commonly they reported clumsiness,
extreme fatigue, weakness, and/or irritability. Worrisome
symptoms reported include shortness of breath and palpi-
tations. Reports of muscle pain secondary to attacks were
consistent with prior literature: 41.3 % reported muscle
pain during attacks and 62.0 % reported muscle pain after
attacks; only 26.1 % denied any associated muscle pain.
In order to characterize the course of hyperPP, we sur-
veyed subjects regarding the way in which their attacks
have changed over time. Attacks typically increased in
frequency during childhood (91.4 %) and teenage years
(79.7 %). From age 20–39, the trend was more divided
with 52.2 % reporting increasing attack frequency, 30.4 %
reporting no change in frequency, and 17.4 % reporting
decreased frequency. From age 40–69, 60 % increased,
20 % stayed the same, and 20 % decreased in attack fre-
quency. Several subjects commented that their attack fre-
quency has remained constant throughout their lives.
Regarding changes in the severity of muscle weakness
during attacks, in individuals under age 20 there was no
significant trend. Between ages 20–39, 64.3 % reported
improvement, and, from ages 40–69, 55 % reported
improvement while 40 % reported worsening weakness.
Regarding changes in muscle stiffness during attacks over
time, subjects frequently reported worsening stiffness
during childhood (85.1 %) and puberty/teenage years
(60.9 %). From age 20–39, participants evenly reported no
change, worsening, and improvement in muscle stiffness.
From age 40–69, 54.5 % reported worsening and 18.2 %
reported improvement of muscle stiffness. The majority of
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respondents noted progressive permanent muscle weakness
during childhood (69.2 %), while only a minority of indi-
viduals reported such changes during teenage years
(33.3 %) and from age 20–39 (30.0 %). This is particularly
significant as prior literature reports that permanent muscle
weakness is a problem of older adults [8, 13]. In line with
prior literature, 84.6 % of respondents age 40 and up
reported worsening permanent muscle weakness. The
general trend in this study population is one of lifelong
increasing attack frequency, which is particularly prevalent
during childhood and adolescence, improving weakness
during attacks from young adulthood onwards, worsening
muscle stiffness during attacks prior to adulthood, and
progressive permanent muscle weakness during childhood
and after age 40.
In addition to the physical effects of their disease, sub-
jects reported other related hardships. In particular, sub-
jects reported their condition having negative impacts on:
work (68.3 %), overall physical health (59.8 %), school
(57.3 %), family life (37.8 %), overall mental health
(30.5 %), and relationships (25.6 %). Effects on overall
physical health reported included weight gain, inability to
exercise, and cardiac arrhythmias. Severe attacks have
made it difficult if not impossible for some to go to work or
to attend school, and moderate attacks can make activities
more painful and slow to carry out. Family life is similarly
affected by limiting activity with children. Progressive
myopathy with muscle dysfunction, reported by 30.4 % of
subjects, contributes to such limitations. Ages of those
reporting limitations of activity range from 20 to 74 years,
with a median of age of 46. Per subjects’ reports, the
effects of periodic paralysis extend far outside the chro-
nological boundaries of acute paralytic episodes.
We surveyed subjects regarding their emotional and
mental well-being. In thinking about their lives with peri-
odic paralysis, subjects most commonly characterized their
overall mental well-being as satisfied, happy, fulfilled, or
hopeful. A significant minority reported feeling hopeless,
depressed, or lost.
Subjects have experienced difficulties in life secondary
to their hyperPP. Some experiences they shared include
falling in the street and being almost run over, experiencing
social anxiety for fear of an attack, and having to take the
help of others or feeling pitied during an attack.
Recommendations offered by subjects for others with
hyperPP include:
• Get educated and seek support
• Join the Periodic Paralysis Association to share expe-
riences with and learn from others
• Teach others about the disorder; do not make excuses
or lie about it
• Adjust your lifestyle, food, activity, and medications as
needed to manage your situation
• Know what works for you—even within the same
family, people have different levels of severity
• Do what you have to do to enjoy your life, keep your
mind off of the condition as much as possible, and
always remembering that it could be worse.
Treatment and management
We asked individuals to characterize the extent to which
they have established adequate therapeutic regimens.
Subjects described their regimens as: ‘‘needs improve-
ment’’ (50.6 %), ‘‘mostly controlled’’ (44.6 %), and
‘‘optimal’’ (4.8 %). Of note, 17.4 % of ‘‘mostly controlled’’
persons denied taking chronic medications, while 61.5 %
of those describing their disease status as ‘‘needs
improvement’’ denied taking chronic medications. Those
not taking chronic medications have a RR of 2.3
(p \ 0.0001) for experiencing inadequate disease control
compared to those taking chronic medications. Therefore,
physicians should be proactive in prescribing medications
Fig. 2 Subjects reported those
areas of the body affected
during attacks. Arms and hands
are just as frequently affected
during attacks as thighs and
calves. Furthermore, facial and
breathing musculature are
affected during attacks in a
significant number of
individuals
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when appropriate. Many participants reported some com-
bination of medications and carbohydrate-rich food as their
primary therapeutic regimen. The majority of subjects
consume medium-sized meals, and 25.4 % consume
smaller-sized meals. Most subjects eat three to five meals a
day and carbohydrate-rich snacks every 2–3 h. Carbohy-
drate sources reported include candy, sugar, bread, and
pasta. Subjects avoid alcohol, a range of high potassium
foods, diet soda, and cold foods and beverages. Concerning
those medications used by ‘‘mostly controlled’’ persons,
21.7 % used hydrochlorothiazide, 21.7 % mexiletine, and
13.0 % flecainide. Individuals tend to use salbutamol or
their chronic medications in the acute setting.
We surveyed participants to identify strategies they find
effective for mitigating acute attacks outside of their long-
term treatment regimens. Common practices include doing
gentle exercise, keeping warm, eating sweet foods,
encouraging muscle relaxation, and drinking water. Dis-
couragingly, 36.0 % are never or are only occasionally able
to abort an attack. Regarding dietary factors that abort or
ameliorate acute attacks, subjects recommended a range of
specific food and beverage items that are carbohydrate-rich
though otherwise seem to reflect personal taste rather than
any nutritional trend. Food items reported include choco-
late bars, cookies, crackers, Coca-Cola, Gatorade, and
sugar. The majority of subjects deny any difference
between the impact of solid versus liquid carbohydrates.
Subjects reported carbohydrates take effect in anywhere
from 10 min to 4–6 h, the majority reporting an effect
within an hour. Subjects commented that it is also very
important to drink a lot of fluids, such as water or tea.
Carbohydrates and hydration appear to be a key part of
nonmedical intervention.
Regarding the association between serum potassium
levels and attack characteristics, no specific trends were
noted. Of those who had their serum potassium levels
measured during attacks, the majority reported being hy-
perkalemic, although several reported being normokalemic
and one reported being hypokalemic. Regardless of
potassium level, subjects usually felt both stiff and weak
during the attacks. No one reported a specific potassium
level threshold they knew of at which attacks would occur.
Paradoxically, 12.7 % of respondents reported episodes of
weakness that improved with potassium intake.
We surveyed individuals regarding the amount of time it
took to arrive at their current therapeutic regimens; 48 % of
subjects reported taking a decade or longer, 20.0 %
5–10 years, 24.0 % 1–5 years, and 8.0 % under a year,
with an average of 11.8 years. Several reported that they
are still trying to find an optimal therapeutic regimen.
Some subjects offered creative and practical solutions
they devised in order to make their home environments
more accommodating to their disease. Many keep at the
bedside items they find helpful during an acute attack, such
as magnesium, sugar, or a cane. Some have placed exercise
equipment in their homes to be able to exercise in a safe
environment. Others installed bathroom railings, made
their homes wheelchair accessible, added raised toilet
seats, or were thoughtful with rug placement. Some require
a one-level home, ride an electric scooter, and/or wear an
emergency medical alert device. Subjects reported doing
low-impact, low-resistance exercises, such as walking,
biking, and swimming, to avoid attacks. Incorporating
these ideas and accommodations into one’s home and
lifestyle may improve safety and help one to deal more
effectively with disease-associated limitations.
Pregnancy, surgery, anesthesia
We surveyed women regarding their experience during
pregnancy. During pregnancy, 91.7 % of women reported
experiencing an increase in attack frequency. A total of
80 % reported an improvement in muscle weakness during
attacks. Regarding muscle stiffness during attacks, 75 %
reported worsening and 25 % improvement. The general
experience during pregnancy tends to be increased attack
frequency, improved muscle weakness during attacks, and
worsened muscle stiffness during attacks.
Subjects were surveyed regarding their experiences with
surgery and anesthesia. Non-anesthetic surgical complica-
tions were reported by 22.8 %, including complete paral-
ysis after surgery for up to 5 days, hyperthermia,
respiratory difficulties, and hypernatremia. One subject
reported avoiding complications ‘‘because [I] always dis-
cussed my condition with the anesthesiologist beforehand
and only used advisable anesthetics.’’ Concerning local
anesthesia, 10.5 % reported being adversely effected;
specific complications included complete paralysis for
hours, respiratory depression, palpitations, and muscle
stiffness. Regarding general anesthesia, 29.9 % reported a
resulting attack. Specifically, subjects reported severe
paralysis involving the muscles of respiration, stiffness,
weakness, hyperthermia, and propofol-induced heavy
weakness. Unfortunately, the anesthetic agents and the
nature of the surgeries were not specified by most subjects.
Notwithstanding, individuals with hyperPP are clearly at
risk for complications from surgery and anesthetics.
Conclusion
Findings in our study that add to current knowledge or that
counter scientific literature regarding hyperPP include the
following points. Progressive myopathy affects approxi-
mately one-third of individuals regardless of the presence
of concomitant myotonia. The RR of thyroid dysfunction in
2612 J Neurol (2013) 260:2606–2613
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the study population is 3.6 compared to the general pop-
ulation; the trend toward an increased rate of cardiac
arrhythmias in this population was not statistically
significant.
A quarter of individuals experienced their sentinel attack
in the second decade of life. Symptomatic myotonia was
reported by 55.8 % of the study population. Alcohol,
changes in humidity, sleep, illness, medication, and men-
struation can trigger attacks. Attacks may affect the facial
and/or the respiratory muscles; some experience loss of
urinary or fecal continence. A total of 12.4 % of subjects
reported severe symptoms between attacks that impair their
activities of daily living. Individuals may experience per-
manent muscle weakness starting in childhood. Those with
no chronic treatment regimen have a RR of 2.3 for
reporting relatively poorer disease control than those taking
long-term medications. During acute attacks, over 10 % of
individuals may note improvement with potassium intake.
Consideration of these factors will allow physicians to
develop appropriate and patient-specific management plans
to best care for each affected individual.
Limitations of our study include recall bias, over- and
under-reporting of symptoms, and the potential mischar-
acterization of myotonia relative to PMC. Furthermore,
subjects’ ability to generate unique responses implies that
some of these responses would have been more widely
reported if they had been included amongst the multiple
choice options. While our study represents among the
largest cohorts of genetically characterized hyperPP
patients to be queried, 94 patients is still a relatively small
number, especially given the possibility of genotype/phe-
notype subsets within what we know to be hyperPP.
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